Bevacizumab increases the incidence of cardiovascular events in patients with metastatic breast or colorectal cancer

Bevacizumab increases the incidence of cardiovascular events in patients with metastatic breast or colorectal cancer

Introduction: The effect of systemic administration of bevacizumab in cancer patients over a 5-year period after the beginning of chemotherapy treatment and comparison with a control group. Methods: The study population consists of adult patients with metastatic breast or colorectal cancer who had n...

Full description

Bibliographic Details
Main Authors: Ioannis Kapelakis, Konstantinos Toutouzas, Maria Drakopoulou, Archontoula Michelongona, Flora Zagouri, Aristotle Mpamias, Paraskevi Pliatsika, Meletios-Athanasios Dimopoulos, Christodoulos Stefanadis, Dimitrios Tousoulis
Format: Article
Language:English
Published: Elsevier 2017-05-01
Series:Hellenic Journal of Cardiology
Subjects:
Bevacizumab
Angiogenesis
Cancer
Coronary artery disease
Vascular endothelial growth factor
Online Access:http://www.sciencedirect.com/science/article/pii/S1109966616302366

Internet

http://www.sciencedirect.com/science/article/pii/S1109966616302366

Similar Items